Skip To Main Content
Max Berger on Muck Rack

Max Berger

Los Angeles
As seen in: Medium, HuffPost, Nature, The Guardian, Wiley Online Library, NBC News, POLITICO, Substack, The Daily Beast, The Toronto Star and
EM Medical Education/Simulation Fellow @UCLAEMRes via @BellevueHosp / @nyulangone & @KeckMedUSC| Red Sox Fan | Chiweenie Dad 🐶 | Thoughts Are My Own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Max

Contact Max, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A natural depsipeptide antibiotic binds the E-site of the bacterial ribosome

|
By Manpreet Kaur, Dmitrii Y. Travin, Max Berger, Manoj Jangra, Martino Morici, Haaris A. Safdari, Dorota Klepacki, Wenliang Wang, Michael Cook, Sommer Chou, Allison K. Guitor, Kalinka Koteva, Min Xu, Linda Ejim, Aline A Fiebig, Brian K. Coombes, Lesley T. MacNeil, Nora Vázquez-Laslop, Alexander S. Mankin, Daniel Wilson, Gerard Wright, Yeganeh Yousefi
| Nature Verified
Abstract A key challenge in addressing the antibiotic resistance crisis is identifying new antimicrobial compounds1. Although natural products produced by fungi and bacteria, particularly actinomycetes, have been the source of most antibiotics discovered over the past 80 years, they have fallen out of favour owing to the frequent rediscovery of known drug scaffolds2. The current perception is that antibiotic-producing actinomycetes have been over-mined and possess little novelty left to yield.
Open in Who Shared Issue with article?

Flipping antimicrobial peptides in the exit tunnel of the bacterial ribosome

|
By Weiping Huang, Max Berger, Haaris A. Safdari, Dorota Klepacki, Helge Paternoga, Chetana Baliga, Daniel Wilson, Nora Vázquez-Laslop, Alexander S. Mankin
| Nature Verified
Abstract Proline-rich antimicrobial peptides (PrAMPs) kill bacteria by binding in the ribosomal nascent peptide exit tunnel. Type II PrAMPs bind in an orientation matching that of the nascent protein, trap the release factors and arrest ribosomes at stop codons. Conversely, Type I PrAMPs bind in an opposite orientation: their N-terminus invades the peptidyl transferase center arresting translation at start codons.
Open in Who Shared Issue with article?

Max Berger (@maxberger.bsky.social)

|
By Max Berger
| bsky.app
This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Open in Who Shared Issue with article?
See all 30 licensed articles (36 Total)